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Microbial drug persistence is a widespread phenomenon in which a subpopulation of microorganisms is able
to survive antimicrobial treatment without acquiring resistance-conferring genetic changes. Microbial per-
sisters can cause recurrent or intractable infections, and, like resistant mutants, they carry an increasing clin-
ical burden. In contrast to heritable drug resistance, however, the biology of persistence is only beginning to
be unraveled. Persisters have traditionally been thought of as metabolically dormant, nondividing cells. As
discussed in this review, increasing evidence suggests that persistence is in fact an activelymaintained state,
triggered and enabled by a network of intracellular stress responses that can accelerate processes of adap-
tive evolution. Beyond shedding light on the basis of persistence, these findings raise the possibility that
persisters behave as an evolutionary reservoir from which resistant organisms can emerge. As persistence
and its consequences come into clearer focus, so too does the need for clinically useful persister-eradication
strategies.Introduction
It was not long after the introduction of antibiotics that the emer-
gence of resistant organisms was first reported (Abraham and
Chain, 1940). Around the same time, a similar phenomenon
began to frustrate physicians. ‘‘Penicillin has undoubtedly saved
lives and limbs of patients suffering from staphylococcal infec-
tions, but it has not usually cured the disease,’’ wrote Joseph
Bigger, an army physician who noticed that antibiotic treatment
often failed to completely sterilize soldiers’ wounds, resulting in
recurrent infections after therapy (Bigger, 1944).
This phenomenon, in which a small subpopulation of microbes
survives the lethal effects of a drug, is referred to as ‘‘persis-
tence.’’ Persistence is distinct from resistance in that, unlike
resistant mutants, persister populations do not expand in the
presence of the toxic compound, and population growth
resumes only once the drug has been removed. Furthermore,
upon retreatment, the recrudescent organisms are as drug sen-
sitive as the initial population, suggesting that unlike resistance,
persistence is a nonheritable phenotype (Figure 1).
Many human pathogens cause recurrent infections despite
appropriate therapy and in the absence of apparent genetic
resistance and thus can be considered persistent. Despite their
clinical importance, the protracted nature of these infections
as well as the lack of suitable animal models has hampered
the study of this phenomenon. Nevertheless, models of persis-
tence in vitro, particularly the study of noninherited drug toler-
ance in bacterial cultures, biofilms, and microfluidic devices,
has helped shed some light on the biological basis of the
persister phenotype.632 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.In this review, we discuss the increasing clinical burden of
microbial persistence and summarize the current understanding
of themechanisms underlying this phenomenon. In particular, we
outline the emerging role of stress responses in potentiating
persister survival and highlight the notion that persistence is an
actively maintained state rather than solely a consequence of
passive growth-rate reduction. Importantly, the stress processes
enabling persistence are also implicated in the accelerated
acquisition of heritable resistance. Thus, we propose that per-
sisters may serve as an evolutionary reservoir from which resis-
tance might emerge and review the clinical evidence lending
credence to this idea. Finally, we discuss potential therapeutic
strategies for the prevention or treatment of persistent infections.
Part I: Drug Persistence in Human Disease
Persistence is widespread and has been described in bacteria,
fungi, parasites, and even cancerous human cell populations
(Table 1). Persistence contributes to the pathogenesis of several
notable human infections that require protracted treatment and
that relapse after therapy. Furthermore, advances in medical
technology allow patients to survive longer with reduced host
defenses or in otherwise compromised states. In the absence
of appropriate host immunity, pathogens that survive drug treat-
ment are more likely to thrive. As a consequence, the prevalence
of persistent infections for which antimicrobial therapy fails to
provide a cure is rising.
Persistence in Bacterial Infections
Among of the best-characterized persistent pathogens are
Mycobacteria, slow-growing aerobic bacteria that include
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Figure 1. Drug Persistence and Recurrent Infection
Schematic model of killing and persistence kinetics during antimicrobial
therapy. Treatment of an initial population of pathogens (I) causes killing of the
majority of cells (II) but fails to eradicate a small subset of persisters (III). When
antibiotic pressure is removed, persisters resume growth, resulting in recurrent
infection of the host (IV). Retreatment results in similar killing kinetics.
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Mycobacteria (NTM). Infections with these organisms require
treatment with unusually protracted courses of combinations
of antibiotics. Mtb therapy can last up to 12 months, and NTM,
such as the Mycobacterium avium complex, can require up to
2 years of treatment. Furthermore, despite apparent microbio-
logic cure, relapse rates of mycobacterial infections are high,
underscoring the clinical importance of persistent subpopula-
tions that are undetectable with current diagnostic technology
(McCune et al., 1956). Consistent with these observations,
detailed studies of infection in mice revealed that treatment of
Mtb infections reduces organism titers but fails to sterilize the
animal (McCune and Tompsett, 1956).
A variety of other bacteria cause persistent infections in
humans. Recurrence of Staphylococcus aureus skin, soft tissue,
and bloodstream infections, for instance, is common, despite
protracted treatment courses (Chong et al., 2013). S. aureus
is also the frequent cause of infections of foreign devices
implanted into humans, including catheters and prosthetic joints.
Despite appropriate therapy, infections on these devices recur
due to the presence of persistent biofilms. Recurrent infection
is also common in the lungs of patients with cystic fibrosis
(CF). Though CF-affected lungs are colonized by hundreds of
bacterial species, Pseudomonas aeruginosa is the most com-
mon cause of recurrent pneumonia in these patients (Zhao
et al., 2012). Antibiotic treatment of pneumonia in CF-affected
patients is the mainstay of therapy; however, antibiotics rarely,
if ever, successfully sterilize the airway. In fact, recent evidence
indicates that antibiotics have minimal impact on the microbial
community structure in these patients, suggesting the exis-
tence of antimicrobial tolerance within this bacterial population(Fodor et al., 2012). A relative of Pseudomonas, Burkholderia
pseudomallei, causes meliodosis, a severe systemic infection
that can recur months to years after apparent clearance by
appropriate antibiotic treatment. Whole-genome sequencing of
recrudescent isolates demonstrated nearly clonal organisms,
indicating that antimicrobial therapy failed to eradicate the initial
infecting population (Hayden et al., 2012).
Persistence in Other Pathogens
Persistence can also complicate therapy for nonbacterial infec-
tions. Biofilm-associated infections with fungi, for example, are
highly recalcitrant to routine antifungal therapy. Even in the
absence of genetic resistance, management ofCandida albicans
infection can frequently require prolonged courses of drugs or
the removal of an infected implanted device.
A form of drug tolerance analogous to persistence, referred
to as dormancy, has been described for the blood stage of
Plasmodium species, the protozoal parasites that causemalaria.
In dormancy, much like in persistence, a small subpopulation of
parasites survives drug treatment and can cause recurrent infec-
tion after cessation of therapy. This phenomenon has been
described for a wide variety of antimalarial drugs, including
mefloquine, atovaquone, and most recently artemisinins, the
most commonly used therapy for malaria worldwide (LaCrue
et al., 2011; Nakazawa et al., 1995, 2002; Teuscher et al.,
2010; Thapar et al., 2005; Witkowski et al., 2010). Similarly, fail-
ure of antiprotozoal drugs to clear bloodstream parasites has
also been described for Babesia, an emerging tick-borne infec-
tion that causes amalaria-like illness (Krause et al., 2008). Impor-
tantly, as has been observed for other classes of persisters, the
bulk of recrudescent parasites appear to remain susceptible to
the initial drugs used in treatment.
The Impact of Persistence in Compromised Host States
Although drug persistence is common inmicrobes and can inter-
fere with treatment, in most cases, antimicrobial therapy suc-
ceeds. It is generally accepted that if drugs successfully kill the
overwhelming majority of an infecting population, intrinsic host
defenses ‘‘mop up’’ the remainder. Advances in medical tech-
nology, however, have resulted in the increased prevalence of
compromised host states. In these individuals, persisters that
would normally be cleared may linger, causing recurrent or
intractable infections.
In addition to increased susceptibility to infection, a number
of immunocompromised states are also associated with an
increased incidence of persistent and recurrent infections. Infec-
tion with HIV and its concomitant T cell immunodeficiency state
is associated with increased severity and recrudescence of
tuberculosis in coinfected individuals (Perrie¨ns et al., 1995). In
solid-organ or hematopoetic stem cell transplant recipients,
who are chronically immunosuppressed to prevent transplant
rejection, infectious complications are a major cause of mortal-
ity. Patients with cancer exhibit impaired mucosal barriers, lead-
ing to the development of oral candidiasis, which can be kept at
bay but not eradicated using local antifungal therapy. Evaluation
of isolates of C. albicans and C. glabrata from such patients
demonstrated the presence of drug-tolerant populations and
revealed that patients with prolonged fungal carriage had sig-
nificantly higher levels of persisters (Lafleur et al., 2010).
Similarly, infection with the protozoan parasite Babesia microti,
which responds well to therapy in normal hosts, recrudesces inCell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc. 633
Table 1. Human Pathogens Associated with Persistent Infection
Pathogen
Duration of
Treatmenta
Number of
Drugsb Persistence Characteristics Hosts Susceptible to Persistent Infection
Bacteria
Mycobacteria
Mycobacterium tuberculosis months 4 slow clearance all, particularly HIV
Nontuberculous Mycobacteria months–years 3–4 slow clearance, recurrence all, particularly bronchiectasis and HIV
Other Bacteria
Staphylococcus aureus weeks–lifelong 1–2 biofilm, recurrence implanted material
Escherichia coli days–weeks 1 biofilm urinary catheters
Pseudomonas aeruginosa days–weeks 1–2 recurrence CF, immunocompromised
Burkholderia pseudomallei weeks 1–2 recurrence all
Burkholderia cenocepacia days–weeks 1–2 recurrence CF
Fungi
Candida species days–lifelong 1 slow clearance, recurrence cancer, immunocompromised, HIV
Parasites
Plasmodium falciparum days 1–2 recrudescence (artemisinins) all
Babesia species weeks–months 1–2 recurrence immunocompromised
Mammalian Cells
Tumor cells months varies recurrence all
CF, cystic fibrosis.
aThe range of treatment duration.
bThe typical number of drugs required to achieve apparent eradication of the organism.
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seemingly appropriate therapy (Krause et al., 2008).
In addition to these impairments in host immunity, compro-
mised host states related to the implantation of cardiac devices,
prosthetic joints, devices interacting with the CNS, and other
foreign bodies are increasing as the population ages. Treatment
of microbial biofilms that form and infect these devices is ineffec-
tive and often requires dangerous and costly removal of the
implant because of the persistence of a small nucleus of surviv-
ing microbes.
Human Cancer Persisters
Noninherited drug tolerance may extend beyond the realm of
infectious organisms. A recent study of non-small cell lung
tumors identified a subpopulation of reversibly drug-tolerant
cancer cells that survived therapy with tyrosine kinase inhibitors
(Sharma et al., 2010). Interestingly, this tumor cell line was able to
maintain growth in the presence of continued chemotherapy.
Furthermore, the drug-tolerant phenotype was mediated
through a signal-transduction cascade, resulting in epigenetic
modifications within the cell, rather than genetic mutations. Inhi-
bition of histone deacetylase prevented the tolerant state, and it
was suggested that the epigenetic modifications involved
occurred as part of a cellular stress response program.
These observations underscore the clinical importance of
persistence in human disease and indicate that persister forma-
tion is a core survival strategy in both prokaryotic and eukaryotic
organisms.
Part II: Mechanisms of Drug Persistence
The rising clinical burden of persistence stresses the need to bet-
ter understand the mechanisms underlying persister formation
and maintenance. Despite the paucity of appropriate animal634 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.models, the study of persistence in cultures and biofilms, cell-
fate mapping experiments using microfluidic devices, and a
deepened understanding of antimicrobial toxicity pathways
have helped shed light on the basis of persistence in pathogens
andmodel organisms. Bacterial persistence can arise spontane-
ously or be environmentally induced. These distinct persister
classes, as well as the mechanisms thought to allow their gener-
ation and survival, are discussed below.
Spontaneous Persistence
The existence of a small fraction of persisters among growing,
isogenic microbes has been hypothesized to reflect a popula-
tion-level strategy of survival in a rapidly changing environment.
In this ‘‘bet-hedging’’ view, phenotypic switching of a few organ-
isms to a dormant or protected state occurs spontaneously and
continuously in any growing microbial population regardless of
the presence of a drug (Kussell et al., 2005).
It has been hypothesized that stochastic variation at the level
of gene expression may engender such pre-exisiting pheno-
typic heterogeneity (Balaban et al., 2004). In particular, toxin/
antitoxin (TA) systems, two-gene operons that encode a cellular
poison and its antidote and are common throughout the bacte-
rial kingdom, have been implicated in the control of persis-
tence. When in excess, the toxin components typically increase
the frequency of bacterial persisters in culture. For instance, in
Escherichia coli, overexpression of the toxin HipA, or a muta-
tion in this gene that desensitizes HipA to its antitoxin HipB,
leads to a 10- to 10,000-fold increase in the frequency of
persistence to ampicillin and ciprofloxacin (Falla and Chopra,
1998; Moyed and Bertrand, 1983). Similarly, overexpression
of the toxin components of the RelE/B, MazF/E, YafQ/DinJ,
MqsR/A, HigB/A, and CcdA/B TA systems enhances persis-
tence to several antibiotics (Maisonneuve et al., 2011; Tripathi
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does not dramatically affect persister formation, deletion of
multiple TA loci does cause an appreciable drop in the number
of persisters (Maisonneuve et al., 2011), suggesting that,
although redundant, TA systems play a role in spontaneous
persistence.
Variation in the expression of a large number of other genes
can also affect persistence or the ability of bacteria to grow in
the presence of drug. These include global regulators, genes
involved in metabolism, and stress-response components (De
Groote et al., 2009; Dhar and McKinney, 2010; Do¨rr et al.,
2009; Hansen et al., 2008; Murakami et al., 2005; Spoering
et al., 2006; Wakamoto et al., 2013). In a recent example,
Mycobacterial growth in the presence of the antibiotic isoniazid
was directly correlated to stochastic variation in the pulsatile
expression of KatG, a catalase peroxidase required for process-
ing and activation of the drug. Specifically, slow-pulsing cells,
which processed less drug, survived longer than fast-pulsing
bacteria (Wakamoto et al., 2013).
Genes affecting survival under stress may be particularly
prone to epigenetic plasticity. Although this question has not
been widely addressed, large-scale transcriptional analysis of
a clonal population of Plasmodium falciparum found that
stochasticity is an intrinsic property of the expression of gene
families involved in host-parasite interactions, suggesting that
variability in these genes might improve the persistence of an
infecting population (Rovira-Graells et al., 2012). In addition to
stochastic gene-expression variation, phenotypic heterogeneity
in drug sensitivity may result from built-in deterministic mecha-
nisms. For instance, asymmetric growth of Mycobacterium
smegmatis gives rise to daughter cells of different sizes and
with different elongation rates, and the slower-growing progeny
are less susceptible to multiple drugs (Aldridge et al., 2012).
Environmentally Induced Persistence
A number of environmental signals can modulate the level of
persistence in an isogenic microbial population. This phenome-
non has been best studied in bacterial cultures, wherein a variety
of noxious cues have been found to increase the frequency of
persistence (Figure 2).
Heat shock, for example, increases the survival of both
Acinetobacter baumannii and P. aeruginosa in the presence of
aminoglycosides or b-lactams, respectively (Cardoso et al.,
2010; Murakami et al., 2005). Oxidative stress and DNA dam-
age caused by treatment with paraquat, hydrogen peroxide,
or sublethal doses of antibiotics promote persistence to fluoro-
quinolone antibiotics in both E. coli and P. aeruginosa (Do¨rr
et al., 2009; Mo¨ker et al., 2010; Vega et al., 2012; Wu et al.,
2012). Similarly, bacterial envelope stress has been associated
with enhanced persister formation (Murakami et al., 2005;
Poole, 2012), as has signaling mediated by soluble quorum
sensing (QS) molecules including phenazine pyocyanin in
P.aeruginosa, peptide alarmones in Streptococcus mutans,
and indole, a stationary-phase QS molecule secreted and
sensed by a wide range of bacteria (Kayama et al., 2009; Leung
and Le´vesque, 2012; Mo¨ker et al., 2010; Vega et al., 2012).
Nutrient starvation and diauxic carbon-source transitions can
also induce persistence (Amato et al., 2013; Betts et al.,
2002; Fung et al., 2010; Nguyen et al., 2011). In fungi, environ-
mental conditions have similarly been suggested to affect drugsusceptibility (Kucharı´kova´ et al., 2011; Pettit et al., 2010).
Biofilm-encased or stationary-phase cells, which are deprived
of certain nutrients and may be subjected to QS signaling,
exhibit persistence at levels typically orders of magnitude
higher than those of logarithmically growing organisms (Keren
et al., 2004; LaFleur et al., 2006).
Importantly, data suggest that in some cases, bacterial persis-
tence that appears spontaneous may in fact have been environ-
mentally induced. Specifically, maintenance of E. coli cultures in
log phase through repeated reinoculation leads to the loss of a
detectable persister population. These data suggest that per-
sisters found in actively growing, low-stress populations may
in fact represent leftover cells from high-stress stationary-phase
inoculums rather than actively growing bacteria that have
switched phenotypes spontaneously (Keren et al., 2004).
Together, these data underscore the role of environmental
parameters such as nutrient availability, population density,
and oxidative stress in the modulation of the persistence levels
in a population.
Stress-Response Pathways Enable Drug Persistence
Whether persistence is acquired spontaneously or is environ-
mentally induced, there is increasing evidence, particularly in
bacteria, for the active involvement of various and intercon-
nected intracellular stress responses (Poole, 2012).
In bacteria, both spontaneous and stress-induced persistence
have been shown to depend on the stringent response (SR). The
SR, which can be triggered by a range of cues, depends onRelA-
and SpoT-mediated synthesis of (p)ppGpp, an alarmone that
broadly modulates gene expression to promote cell survival
(Potrykus and Cashel, 2008). In E. coli hipA7 mutants, which
express a gain-of-function mutation in the HipA toxin and exhibit
elevated spontaneous persister frequencies (Balaban et al.,
2004), simultenously deleting relA and spoT eliminates persis-
tence (Korch et al., 2003). The broad toxic effects of HipA on
nucleic acid and protein synthesis (Korch and Hill, 2006) may
be responsible for triggering theSR. In addition, genetic knockout
of relA and spoT in bothP. aeruginosa andE. coli diminishes star-
vation-induced persistence, biofilm drug tolerance, and persis-
tence in vivo (Fung et al., 2010; Nguyen et al., 2011). Recently,
E. coli persistence induced by diauxic carbon-source transition-
ing has also been found to require the SR (Amato et al., 2013).
Starvation-induced drug tolerance in M. tuberculosis has been
suggested to depend on RelMtb, a RelA homolog (Betts et al.,
2002). Interestingly, a gain-of-function mutation in relA causing
permanent activation of the SR generated a high-persistence
phenotype in a primary isolate of S. aureus identified in human
infection (Gao et al., 2010).
Activationof thebacterialSOSresponse toDNAdamage,much
like theSR, has been associatedwith induction ormaintenance of
persistence. E. colimutants lacking recA, recB, or lexA, key SOS
response genes, are more susceptible to quinolones, and in the
presence of these drugs, the frequency of both spontaneous
and induced persistence is reduced by 10- to 100-fold (Do¨rr
et al., 2009; Fung et al., 2010;Wu et al., 2012). Conversely, consti-
tutive expression of SOS response genes enhances drug toler-
ance (Do¨rr et al., 2009). Thus, persistence to quinolones is aided
and partially depends on the cell’s ability to repair DNA damage.
A number of other stress-response pathways have been impli-
cated in persister formation. These include the oxidative stressCell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc. 635
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shock response, both of which are involved in indole-induced
persistence in E. coli (Grant and Hung, 2013; Vega et al., 2012;
Wu et al., 2012). Genes regulating the heat-shock response
have been reported to play a role in tolerance to aminoglyco-
sides (Cardoso et al., 2010), and the alternative sigma factor
RpoS, which coordinates the general stress response, is impor-
tant in QS-induced persistence in P. aeruginosa (Kayama et al.,
2009; Murakami et al., 2005).
Taken together, these data suggest that centralized stress
responses are at the core of the persister phenotype. Both envi-
ronmental factors and stochastic endogenous processes can
give rise to stress and thus contribute to the generation of
multi-drug-tolerant persisters.
Mechanisms of Survival
Most stress responses lead directly or indirectly to a slowing or
stalling of bacterial growth and division. This slowed or arrested
cellular growth has been suggested as the major factor underly-
ing drug persistence, given that the ability of antibiotics to kill
bacteria is generally proportional to their growth rate (Eng
et al., 1991). Reduced growth rates have indeed been correlated
with increased drug persistence both in vitro (Aldridge et al.,
2012; Balaban et al., 2004; Keren et al., 2004; Shah et al.,
2006) and in vivo, when bacterial growth tapers over the course
of an infection due to immune pressure or lack of nutrients (Levin
and Rozen, 2006). The reduced rates of DNA replication, trans-
lation, cell-wall synthesis, and metabolism directly targeted by
antibiotics have been assumed to account for the relative drug
tolerance of dormant bacteria. Although stalled biosynthesis
probably promotes persistence, its effects are difficult to untan-
gle from those of accompanying stress-response processes,
and it is becoming clear that many active cellular processes
occurring in parallel with growth-rate reduction are central for
cellular survival in a toxic environment.
For instance, a number of active intracellular detoxification
mechanisms that can be triggered by stress play an important
role in persistence. Multidrug efflux pumps are upregulated in
response to various cues, including oxidative stress and QS
(Hirakawa et al., 2005), and can contribute to both in vitro and
in vivo persistence. For example, paraquat-induced persistence
in E. coli in vitro is dependent on the AcrAB-TolC multidrug
efflux system (Wu et al., 2012). Similarly, drug tolerance in a
Mycobacterial infection model was reported to depend on drug
efflux pumps induced bymacrophage-mediated oxidative stress
(Adams et al., 2011). In some cases, persisters exhibit a revers-
ible defect in drug uptake (Allison et al., 2011b). Beyond active
efflux, detoxification can take other forms. For example, the
exposure of bacteria to antibiotics can enhance their synthesis
of nitric oxide, which chemically modifies certain drugs and
inactivates them (Gusarov et al., 2009; Shatalin et al., 2011). In
Mycobacteria, stress can also promote alternative metabolic
pathways that produce lower levels of reactive oxygen species
(ROS), thus elevating the threshold for antibiotic-mediated death
(Baek et al., 2011). Finally, generation of ROS following antibiotic
exposure has been proposed to contribute to the lethal effects of
antimicrobials (Dwyer et al., 2007; Foti et al., 2012; Kohanski
et al., 2007, 2008; Wang and Zhao, 2009). Although the role of
ROS in antibiotic-mediated bacterial killing has recently become
amatter of debate (Keren et al., 2013; Liu and Imlay, 2013), active636 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.mechanisms of oxidative stress relief have been found to pro-
mote drug tolerance. For example, activation of catalase and
superoxide dismutase, antioxidant enzymes, promotes stress-
induced drug persistence and biofilm-associated persistence
in bacteria and fungi (Belenky and Collins, 2011; Nguyen et al.,
2011; Shatalin et al., 2011; Van Acker et al., 2013).
In addition to detoxification, stress can promote active
microbial mechanisms of physical sequestration. For instance,
bacterial surface adhesiveness and the subsequent formation
of protective biofilms can be enhanced in response to sublethal
antibiotic treatment and other stresses (He et al., 2012; Hoffman
et al., 2005). Although tolerancemechanisms in biofilms are still a
subject of intense investigation, it is clear that mechanisms other
than dormancy are at play (Høiby et al., 2010).
Interestingly, persistence and cellular growth may not always
be incompatible. Although spontaneous E. coli persisters have
been shown to be growth arrested (Balaban et al., 2004), a
microfluidics-based study following the fate of individual
Mycobacteria during antibiotic treatment found that the apparent
stability of persister numbers was in fact due to a dynamic state
of balanced death and division, rather than generally arrested
growth (Wakamoto et al., 2013).
Together, these recent studies challenge the prevailing view
that persistence is solely linked to passive dormancy and sug-
gest that these cells are engaged in a host of active processes
that allow survival (Adams et al., 2011; Nguyen et al., 2011;
Wakamoto et al., 2013).
Part III: Persistence-Enabling Stress Responses
Accelerate Acquisition of Resistance
The discovery that cellular activity and division can occur during
persistence raises the possibility that persisters function as an
intermediate state in the elaboration of heritable drug resistance.
Residual cell division combined with active survival mechanisms
could support or even enhance the development of heritable
genetic changes, because many of the same stress-response
programs important for the generation and survival of persisters
can also accelerate genome-wide mutagenesis and horizontal
gene transfer. Thus, persisters may represent a pool of adap-
tively evolving organisms from which resistant mutants can
emerge (Figure 2).
Stress Responses Promote Adaptive Mutation
Although in theory low rates of cell division in persisters under
drug pressure may suffice to give rise to resistance-conferring
mutations, stress responses might vastly accelerate this pro-
cess. Recently, exogenous stress has been shown to promote
genome instability, or ‘‘adaptive mutation,’’ leading to fast-
tracked population diversification.
Recent systems-level analyses have uncovered that overlap-
ping stress responses (SR and SOS) function as upstream hubs
of a program of adaptive mutagenesis in E. coli, S. aureus, and
P. aeruginosa (Al Mamun et al., 2012; Cirz et al., 2006, 2007).
For example, activation of the SR by starvation stress increases
basal mutation rates in E. coli through activation of the error-
prone DinB polymerase (Petrosino et al., 2009). Similarly, muta-
genic polymerases are induced in S. aureus and P. aeruginosa
following induction of the SOS response (Cirz et al., 2006, 2007).
In addition to the activity of microbial stress-response sys-
tems, bactericidal antibiotic therapy alone has been shown to
Stress Response
Intracellular stress Nutrient starvation Oxidative stress DNA damage
Adaptive Evolution
Quorum sensing
Persistence
RESISTANCE
Figure 2. Stress Responses Link
Persistence, Adaptive Evolution,
and Resistance
In this model, microbial responses to endogenous
or exogenous stresses promote survival as well as
genetic plasticity. Persistent organisms undergo
rapid adaptive evolution and can function as a
reservoir for the elaboration of drug resistance.
Cell Host & Microbe
Reviewincrease rates of mutagenesis. Treatment of bacteria with suble-
thal doses of bactericidal antibiotics results in genome-wide
mutations through stimulation of ROS production and through
RpoS-mediated activation of the error-prone polymerase PolIV
(Gutierrez et al., 2013; Kohanski et al., 2010; Nair et al., 2013).
Selection of such resistance mutations by antibiotics can occur
at drug concentrations orders of magnitude below the inhibitory
level of susceptible bacteria (Gullberg et al., 2011).
Interestingly, a link between ROS-specific mutagenesis by
sublethal antibiotics and microbial stress-response pathways
has recently been demonstrated. In E. coli lacking the SR (both
relA and spoT), treatment of cultures with sublethal antibiotics
failed to generate adaptive resistance, a phenomenon that was
linked to reduced rates of oxidative stress in the SR null organism
(Nguyen et al., 2011). This suggests that an intact SR pathway is
required for an antibiotic-stress-caused adaptive mutation to
develop.
The structure of bacterial communities may also play an
important role in the occurrence of adaptive mutations (Zhang
et al., 2011). Higher mutation rates have been found in biofilm-
associated P. aeruginosa (Driffield et al., 2008) and S. aureus
(Ryder et al., 2012) than in planktonic cultures, and these
increased rates appear to be linked to higher levels of oxidative
stress in the biofilm community. Thus, features consistent with
persister formation—exposure to bactericidal antibiotics, activa-
tion of stress-response pathways, and biofilm association—
create a suitable environment for adaptive mutation to occur
within this subpopulation.
Stress Responses Promote Horizontal Gene Transfer
A second major mechanism by which antibiotic resistance is
elaborated is by the sharing of resistance determinants on
mobile genetic elements.Stress-responsepathways, particularly
the SOS, have also been found to promote horizontal gene trans-Cell Host & Microbefer in bacteria. Induction of the SOS
response by the quinolone class of antibi-
otics increases horizontal gene transfer
frequency in E. coli and Vibrio cholera
(Beaber et al., 2004), specifically promot-
ing the sharing of integrative conjugative
elements that result in resistance to ami-
noglycosides, lincosamides, and antifo-
late antibiotics.
In organisms that lack a traditional
SOS system, alternative stress-response
pathways have been found to promote
gene transfer. In Streptococcus pneumo-
niae, which lacks an SOS system,
competence induction by antibiotics has
been linked to activation of QS signalsas a response to the management of misfolded proteins caused
by aminoglycoside treatment (Prudhomme et al., 2006; Stevens
et al., 2011). Higher rates of phage transduction, which can
disseminate antibiotic resistance determinants, have also been
reported with treatment of some antibiotics (Zhang et al.,
2000). Interestingly, environmental stress from sources other
than antibiotics has similarly been shown to increase rates of
horizontal gene transfer in bacterial communities (Stecher
et al., 2012). Biofilm formation, in addition to increasing rates
of adaptive mutation, can also promote horizontal gene trans-
fer in S. aureus (Savage et al., 2013). Thus, stress-response
pathways and microbial community structures that favor the
development of persisters can also potentiate horizontal gene
transfer.
Part IV: Is Persistence Linked to Drug Resistance
In Vivo?
Just as our understanding of persisters in vivo remains limited,
characterization of how drug resistance emerges in patients
remains largely obscure. The increasing use of whole-genome
sequencing of microbes is beginning to shed light on pathogen
dynamics during persistent infection.
For example, longitudinal whole-genome sequencing of
S. aureus isolates in a patient with persistent infection demon-
strated the accumulation over several months of a small number
of point mutations associated with antibiotic resistance that
would not have been detected by standard laboratory practice
(Mwangi et al., 2007). This dynamic structure of bacterial popu-
lations was further explored using whole-genome sequencing of
a CF pneumonia outbreak strain,Burkholderia dolosa, in multiple
consecutive patients. In this longitudinal analysis, near-continual
parallel adaptive evolution occurred among isolates in very
similar genetic loci involved in antibiotic resistance and oxygen13, June 12, 2013 ª2013 Elsevier Inc. 637
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whole-genome sequencing of recrudescent infection with
Burkholderia pseudomallei established that infection recur-
rences did not result from reinfection but rather from regrowth
of persisting organisms. The study further identified in these iso-
lates a number of antibiotic-resistance-conferring mutations.
Although these antibiotic-resistant mutants may have been pre-
sent in the initial infecting population and subsequently selected
for, the nature of the genetic changes and the detection of spe-
cific mutations typically associated with recurrent isolates, but
not with environmental strains, suggested that evolution toward
resistance had occurred in the host (Hayden et al., 2012).
Whole-genome sequencing of populations of microbes, rather
than just individual clones, has also disclosed significantly
greater community complexity than previously appreciated.
This is particularly important in the context of antibiotic resis-
tance. In vitro, populations of bacteria under antibiotic pressure
have been found to be composed of mixed subpopulations of
susceptible and resistant organisms. A small number of altruistic,
resistant organisms sensing environmental stress can lead to a
population-wide drug-tolerant state by secreting indole (Lee
et al., 2010). In an in vivo example, whole-genome sequencing
of Mtb populations in sputum from patients who experienced
recrudescent infection, including analysis of very-low-abun-
dance variants in the population, revealed a remarkable amount
of coexisting genetic diversity and the frequent emergence of
resistant strains at low frequencies (Sun et al., 2012).
The links between dormancy in Plasmodium species and the
development of resistance to antimalarial compounds in vivo
remain unclear. Resistance to artemisinin in P. falciparum has
recently emerged and is likely to spread more widely (Miotto
et al., 2013). Artemisinin resistance was originally identified by
a delay in the clearance of parasites from the bloodstream
(Amaratunga et al., 2012; Dondorp et al., 2009). A recent SNP
analysis of parasites with delayed clearance identified four asso-
ciated polymorphisms, including mutations associated with a
DNA damage tolerance pathway (Takala-Harrison et al., 2013).
Mathematical modeling experiments have suggested that
reduced artemesinin susceptibility is related to reduced ring-
stage susceptibility, the life stage associated with dormancy
(Saralamba et al., 2011). Modeling has also suggested that
recrudescence is an important clinical feature for the dissemina-
tion of de novo drug resistance (White et al., 2009). Though these
associations provoke interest in a potential link between
dormancy and artemesinin resistance, more research is needed
to draw meaningful conclusions.
Part V: Toward Therapeutic Eradication of Persisters
As discussed above, not only do microbial persisters thwart our
efforts to treat infection, but they may also act as reservoirs of
actively and adaptively evolving organisms. Although a causal
relationship between persistence and resistance remains to be
definitively established, the possibility that persisters may give
rise to resistant mutants further underscores the importance of
developing methods to eradicate such phenotypically drug-
refractory subpopulations. As our mechanistic understanding
of persistence deepens, new strategies for targeting these cells
specifically or for enhancing their susceptibility to killing by exist-
ing antimicrobials are being devised (Allison et al., 2011a).638 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.One possibility is targeting the stress responses that coordi-
nate the persistent phenotype and the generation of resistance.
Although work in this area is still in its infancy, a few promising
studies have begun to explore this approach (Cirz and Romes-
berg, 2007). For example, inhibition of the SOS response either
by deletion of recA or by overexpression of an uncleavable
mutant of the LexA repressor potentiates killing by quinolones,
aminoglycosides, and b-lactams (Kohanski et al., 2007; Lu and
Collins, 2009). Supplementing antibiotic therapy with engineered
bacteriophage constitutively expressing an uncleavable LexA
repressor improved survival in a murine model of acute E. coli
infection and even improved killing of genetically drug-resistant
mutants. Furthermore, combination therapy with these bacterio-
phages substantially reduced the rate of antibiotic-induced
mutation and resistance emergence in sublethally treated bacte-
ria (Lu and Collins, 2009). Small-molecule screens have identi-
fied RecA inhibitors that might similarly enhance antibiotic
activity and prevent adaptive mutation in bacterial pathogens
(Wigle et al., 2009). Similarly, preventing the derepression of
the SOS response or ablating SOS-induced alternative polymer-
ases prevents UV-induced adaptive mutation in S. aureus (Cirz
et al., 2007).
Interestingly, bacteriophage engineered to interfere with the
oxidative stress response by overexpressing SoxR also potenti-
ates antibiotic therapy (Lu and Collins, 2009). Other findings sug-
gest that drugs targeting the SR (Wexselblatt et al., 2012) or
interfering with envelope-repair pathways (Lee et al., 2009)
may also help prevent persister formation or enhance bacteri-
cidal antibiotic activity.
Another strategy is interference with persister survival mech-
anisms. Therapies could target residual metabolic activity in
persisting organisms, for example. Indeed, inhibition of the
mycobacterial proteasome or ATP synthase has been shown
to promote the death of nongrowing M. tuberculosis (Andries
et al., 2005; Gandotra et al., 2007; Lin et al., 2009). Because of
the protective role biofilms play in drug- and immune-related
persistence, the processes required for their formation are also
being investigated for potential targets. Small-molecule screens
have been designed for finding candidate biofilm inhibitors
(Cegelski et al., 2009; Junker and Clardy, 2007). Among others,
one group discovered compounds that prevent the biogenesis
of pili and curli, extracellular bacterial fibers that mediate sub-
strate attachment in the initial phases of biofilm formation (Aberg
and Almqvist, 2007). Although treatment susceptibility was not
assessed, these compounds effectively reduced the virulence
of uropathogenic E. coli in a murine infection model (Cegelski
et al., 2009). Therapeutic strategies to disaggregate existing bio-
films are also being considered (Boles andHorswill, 2008; Lu and
Collins, 2007). Detoxification mechanisms such as efflux pumps
are being investigated as new antibiotic targets or as adjuvants
to existing therapies (Ferna´ndez and Hancock, 2012). Persisters
can also be antagonized by potentiating antibiotic toxicity
though the enhancement of drug uptake. For example, amino-
glycoside uptake by persisters and the efficacy of aminoglyco-
side treatment of catheter-associated E. coli infection in mice
can be increased through coadministration of specific metabo-
lites that help power the transmembrane proton motive force
(Allison et al., 2011b; Lu and Collins, 2009). Finally, the use of
adjuvants that maximize antibiotic-induced intracellular ROS
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Reviewproduction is also being explored (Brynildsen et al., 2013; Grant
et al., 2012).
Drug screens have traditionally focused on identifying com-
pounds lethal to microbes in stress-free in vitro culture environ-
ments. Although this has been a successful way to identify drug
targets, it is becoming clear that many microbial processes not
required for idealized life in vitro are essential for survival over
the course of infection and treatment in humans (Barczak and
Hung, 2009). Such processes, which include both persistence
and virulence, are intimately linked to dynamic and complex
networks of stress responses that orchestrate phenotypic adap-
tation. Learning more about these processes and their role in
infection is likely to yield a rich trove of potential new drug targets
and hopefully will lead tomore effective therapies against persis-
tent, relapsing, and resistant organisms.
Conclusion and Future Directions
Persistent and recurrent infections in humans are common, and
their frequency is rising. Despite this, our understanding of anti-
microbial treatment failure remains limited. Though insight into
microbial drug tolerance has been gained using in vitro systems,
the persister phenotype has remained only partially character-
ized. Going forward, innovative approaches to persister isolation
and molecular definition are urgently needed to more deeply
explore mechanisms involved in induction, maintenance, and
exit from the persister state. Furthermore, animal models that
faithfully recapitulate human infection and treatment courses
should be devised to corroborate culture-based data. Lastly,
for exploring persistence and resistance dynamics in vivo, longi-
tudinal studies of microbial population size, diversity, and evolu-
tion occurring within individual patients during the course of
infection and treatment should be initiated. Although indirect
evidence suggests that the persister state may promote the
emergence of resistance, no definitive experiment has estab-
lished that this is the case. An integrative approach that com-
pares the results of culture systems, animal models, and natural
history cohorts of primary human infection will facilitate the
elucidation of persistence mechanisms, help to determine the
magnitude of the impact of persistence to human treatment
failure and drug resistance, and usher in new approaches to
the treatment and eradication of infectious diseases.
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